SEC 13F Intelligence

Managers / Q1 2024 · view latest →

Artia Global Partners LP

CIK 0001937964 · 1 SE 3RD AVENUE, STE 2120, MIAMI, FL, 33131 · 3057101384

Reported Value
$498M
Q1 2024
Positions
49
Filings on Record
15
2019–present window
Filed
May 15, 2024
original filing

Summary

Artia Global Partners LP reported $498M in U.S.-listed holdings across 49 positions for Q1 2024.

Its largest position, NVO, represents 17.9% of the portfolio.

Compared with Q4 2023, the fund opened 24 new positions and exited 6.

Portfolio Metrics

Turnover
+17.3%
vs prior filed quarter
Top-10 Concentration
+64.9%
share of reported value
Largest Position
+17.9%
Novo Nordisk A S
New / Exited
24 / 6
positions this quarter

Methodology: turnover is min(value bought, value sold) ÷ average reported value across the two quarters — value-based, so market moves inflate it slightly versus a share-based measure. Concentration and largest position are shares of the filing’s total reported value, options excluded. New/exited counts compare against the prior filed quarter. All figures derive solely from the fund’s 13F filings.

Reported Value by Quarter

13F Reported Value
Q4 ’22: $262MQ4 ’22Q1 ’23: $271MQ2 ’23: $290MQ2 ’23Q3 ’23: $241MQ4 ’23: $344MQ4 ’23Q1 ’24: $498MQ2 ’24: $517MQ2 ’24Q3 ’24: $367MQ4 ’24: $280MQ4 ’24Q1 ’25: $395MQ2 ’25: $416MQ2 ’25Q3 ’25: $631MQ4 ’25: $706MQ4 ’25Q1 ’26: $499Mfilingsflow.com

Portfolio Composition

By security type
Common Stock: 56.4%ADR: 24.1%Other: 19.5%
  • Common Stock · 56.4% · $281M
  • ADR · 24.1% · $120M
  • Other · 19.5% · $97M

Quarter-over-Quarter Changes full breakdown →

vs Q4 2023 (amended baseline)

IssuerMoveShare ΔShares nowValue ΔValue now
VRTXVERTEX PHARMACEUTICALS INCNEW+28.9K28.9K+$12M$12M
IRONDISC MEDICINE INCNEW+87.0K87.0K+$5M$5M
CRNXCRINETICS PHARMACEUTICALS INNEW+85.8K85.8K+$4M$4M
DYNDYNE THERAPEUTICS INCNEW+119.5K119.5K+$3M$3M
SWTXUSDSPRINGWORKS THERAPEUTICS INCNEW+53.9K53.9K+$3M$3M
ASCENDIS PHARMA A/SNEW+15.9K15.9K+$2M$2M
IDYAIDEAYA BIOSCIENCES INCNEW+52.5K52.5K+$2M$2M
MERUS N VNEW+50.2K50.2K+$2M$2M

Value changes conflate price moves with buying and selling — share changes are the real signal. Share counts are not split-adjusted.

Holdings — Q1 2024

47 positions
Export to Excel
#IssuerClass% PortfolioValue ↓Shares
1NVONOVO-NORDISK A Shistory →ADR17.85%$89M691.7K
2LLYELI LILLY & COhistory →COM14.48%$72M92.6K
3MRKMERCK & CO INChistory →COM10.06%$50M379.2K
4VKTXVIKING THERAPEUTICS INChistory →COM7.15%$36M433.6K
5ABBVABBVIE INChistory →COM3.32%$17M90.8K
6ITCIEURINTRA-CELLULAR THERAPIES INChistory →COM2.92%$15M210.1K
7ARGXARGENX SEhistory →SPONSORED ADR2.71%$13M34.2K
8AZNNASTRAZENECA PLChistory →SPONSORED ADR2.60%$13M190.8K
9VRTXVERTEX PHARMACEUTICALS INChistory →COM2.43%$12M28.9K
10AXSMAXSOME THERAPEUTICS INChistory →COM1.41%$7M87.8K
11OCULOCULAR THERAPEUTIX INChistory →COM1.33%$7M724.7K
12CYTKCYTOKINETICS INChistory →COM NEW1.26%$6M89.5K
13NBIXNEUROCRINE BIOSCIENCES INChistory →COM1.25%$6M45.0K
14IRONDISC MEDICINE INChistory →COM1.09%$5M87.0K
15PCVXVAXCYTE INChistory →COM1.05%$5M76.3K
16APGEAPOGEE THERAPEUTICS INCCOM0.82%$4M61.6K
17CRNXCRINETICS PHARMACEUTICALS INCOM0.81%$4M85.8K
18PTGXPROTAGONIST THERAPEUTICS INCCOM0.72%$4M124.4K
19DYNDYNE THERAPEUTICS INCCOM0.68%$3M119.5K
20IM8NINSMED INCCOM PAR $.010.64%$3M118.2K
21SWTXUSDSPRINGWORKS THERAPEUTICS INCCOM0.53%$3M53.9K
22ASCENDIS PHARMA A/SSPONSORED ADR0.48%$2M15.9K
23IDYAIDEAYA BIOSCIENCES INCCOM0.46%$2M52.5K
24MERUS N VCOM0.45%$2M50.2K
25VRNAVERONA PHARMA PLCSPONSORED ADS0.42%$2M130.8K
26NVLSEURALPINE IMMUNE SCIENCES INCCOM0.41%$2M51.7K
27CHARLES RIV LABS INTL INCCOM0.38%$2M6.9K
28JANXJANUX THERAPEUTICS INCCOM0.36%$2M47.9K
29SLNOEURSOLENO THERAPEUTICS INCCOM0.35%$2M40.9K
30XENEXENON PHARMACEUTICALS INCCOM0.35%$2M40.0K
31ARVNARVINAS INCCOM0.33%$2M40.0K
32PLRXPLIANT THERAPEUTICS INCCOM0.30%$1M100.0K
33MREOMEREO BIOPHARMA GROUP PLCSPON ADS0.28%$1M421.4K
34NEWAMSTERDAM PHARMA COMPANYORDINARY SHARES0.26%$1M54.3K
35RAPT THERAPEUTICS INCCOM0.25%$1M137.3K
36SLNSILENCE THERAPEUTICS PLCADS0.23%$1M52.5K
37EYPTEYEPOINT PHARMACEUTICALS INCCOM NEW0.21%$1M51.5K
38ANNXANNEXON INCCOM0.21%$1M147.5K
39VERAVERA THERAPEUTICS INCCL A0.21%$1M24.3K
40MGNXMACROGENICS INCCOM0.19%$942,18364.0K
41KURAKURA ONCOLOGY INCCOM0.17%$842,06639.5K
42IMVTIMMUNOVANT INCCOM0.14%$691,33721.4K
43BMEABIOMEA FUSION INCCOM0.11%$530,00735.5K
44LRMRLARIMAR THERAPEUTICS INCCOM0.09%$441,66258.2K
45MDGLMADRIGAL PHARMACEUTICALS INCCOM0.08%$415,7811.6K
46PSTXUSDPOSEIDA THERAPEUTICS INCCOM0.06%$274,34686.0K
472JQGRITSTONE BIO INCCOM0.05%$244,58795.2K

Filing History

QuarterReported ValuePositionsFiledTypeLinks
Q1 2026$499M50May 15, 202613F-HRchanges · EDGAR ↗
Q4 2025$706M55Feb 17, 202613F-HRchanges · EDGAR ↗
Q3 2025$631M51Nov 14, 2025RESTATEMENTchanges · EDGAR ↗
Q2 2025$416M37Aug 14, 202513F-HRchanges · EDGAR ↗
Q1 2025$395M38May 15, 202513F-HRchanges · EDGAR ↗
Q4 2024$280M37Feb 14, 202513F-HRchanges · EDGAR ↗
Q3 2024$367M45Nov 14, 202413F-HRchanges · EDGAR ↗
Q2 2024$517M46Aug 14, 202413F-HRchanges · EDGAR ↗
Q1 2024$498M49May 15, 202413F-HRchanges · EDGAR ↗
Q4 2023$344M31Feb 14, 202413F-HRchanges · EDGAR ↗
Q3 2023$241M27Nov 14, 202313F-HRchanges · EDGAR ↗
Q2 2023$290M34Aug 14, 202313F-HRchanges · EDGAR ↗
Q1 2023$271M36May 15, 202313F-HRchanges · EDGAR ↗
Q4 2022$262M25Feb 14, 202313F-HRchanges · EDGAR ↗

13F filings are due up to 45 days after quarter end, so holdings shown here lag the fund’s current book. Source: original SEC filing on EDGAR ↗.